Sansalone C V, Maione G, Aseni P, Mangoni I, De Roberto A, Soldano S, Minetti E, Broggi M L, Civati G
Kidney and Pancreas Transplantation Unit, Niguarda Hospital, Milan, Italy.
Transplant Proc. 2005 Jul-Aug;37(6):2651-3. doi: 10.1016/j.transproceed.2005.06.103.
We examined surgical complications among a group of diabetic type 1 patients (IDDM) with end-stage renal disease (ESRD) who had undergone pancreas-kidney transplantations (PK). Between October 1993 and August 2004, 70 SPK were performed using bladder (n = 14) or enteric (n = 56) drainage. Donors were selected according to standard criteria (mean age, 27.6 years; range, 17-49). All patients received cyclosporine-based immunosuppression. All pancreata functioned immediately, whereas 2 patients needed postoperative dialysis. Four patients (5.7%) lost their pancreatic graft due to vascular thrombosis; both patients underwent urgent allograft pancreaectomy and pancreas retransplantation (re-PT). One of them (1.4%) experienced a venous thrombosis and died due to a pulmonary embolism at 12 hours after re-PT. The other 3 patients had uneventful postoperative courses and were discharged with good pancreatic and renal function. Three patients in the bladder group (21.4%) had an anastomotic leak, which resolved with a bladder catheter. Four patients in the enteric group (7.1%) who experienced an anastomotic leak needed a second surgical procedure but in 3 of them allograft pancreatectomy was necessary. Relaparotomy was required in the other 3 patients due to hemorrhage (1 patient) or occlusion (2 patients). Acute rejection episodes, which occurred in 16 patients (22.8%), were treated with steroid boluses. With a mean follow-up of 72 months (range, 3-129), 2 patients have died at 8 and at 36 months, respectively, after SPK due to acute myocardial infarction (2.9%). Chronic rejection was the leading cause of pancreatic failure in 5 patients (7.1%) and of renal failure in 2 patients (2.8%). Patient, kidney, and pancreas survival rates were 95.8%, 92.9%, and 81.5%, respectively. Surgical complications were the leading cause of pancreatic allograft loss in IDDM and ESRD patients submitted to SPK.
我们研究了一组患有终末期肾病(ESRD)的1型糖尿病患者(胰岛素依赖型糖尿病,IDDM)在接受胰肾联合移植(PK)后的手术并发症情况。在1993年10月至2004年8月期间,共进行了70例胰肾联合移植手术,采用膀胱引流(n = 14)或肠道引流(n = 56)。供体根据标准标准选择(平均年龄27.6岁;范围17 - 49岁)。所有患者均接受以环孢素为基础的免疫抑制治疗。所有胰腺移植后立即发挥功能,而2例患者术后需要透析。4例患者(5.7%)因血管血栓形成失去胰腺移植;这2例患者均接受了紧急移植胰腺切除术和胰腺再次移植(再次PT)。其中1例患者(1.4%)发生静脉血栓形成,在再次PT后12小时因肺栓塞死亡。另外3例患者术后病程平稳,出院时胰腺和肾功能良好。膀胱引流组有3例患者(21.4%)发生吻合口漏,通过留置膀胱导管得以解决。肠道引流组有4例患者(7.1%)发生吻合口漏,其中3例需要再次手术,但其中2例需要进行移植胰腺切除术。另外3例患者因出血(1例)或梗阻(2例)需要再次剖腹手术。16例患者(22.8%)发生急性排斥反应,采用大剂量类固醇治疗。平均随访72个月(范围3 - 129个月),2例患者分别在胰肾联合移植后8个月和36个月因急性心肌梗死死亡(2.9%)。慢性排斥反应是5例患者(7.1%)胰腺功能衰竭和2例患者(2.8%)肾功能衰竭的主要原因。患者、肾脏和胰腺的生存率分别为95.8%)、92.9%和81.5%。手术并发症是接受胰肾联合移植的1型糖尿病和终末期肾病患者胰腺移植失败的主要原因。